PT Roche Indonesia would like to inform healthcare professionals related the new safety concern of immune-related myositis associated with Tecentriq® (atezolizumab).
Dermatomyositis and polymyositis are amongst the most common types of myositis. Diagnosis is based on clinical (muscle weakness, muscle pain, skin rash in dermatomyositis), biochemical (serum creatine-kinase increase), and imaging (electromyography/magnetic resonance imaging) features, and is confirmed with a muscle biopsy. Healthcare professionals are advised to withhold Tecentriq® for moderate or severe (Grade 2 or 3) immune-related myositis and permanently discontinue the drug for recurrent severe or life-threatening myositis (recurrent Grade 3 and Grade 4). Please refer to the attached letter for details information.
Download : DHPC Tecentriq- Immune Myostis IDN-Final.pdf